Pay in 4 interest-free payments of $16.25 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
(2010) Mol Cancer Ther
6 µM confirming the inhibition of NMDA receptors observed in electrophysiological experiments
1-Dimethylethoxy)- 2
which reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice
stem cell renewal and cancer growth
CERC-501 - CAS# 1174130-61-0 60224 (2010) Mol Cancer TherCERC 501, also known as JNJ 67953964, LY 2456302 and Aticaprant, CAS No. 1174130 61 0, is a potent, selective, short acting antagonist of the opioid receptor (KOR) (Ki = 0. 81 nM vs. 24. 0 nM and 155 nM for the opioid receptor (MOR) and opioid receptor (DOR). Aticaprant is under development for the treatment of major depressive disorder and substance use disorders including alcoholism, nicotine addiction, and illicit drug dependence. Aticaprant has
US$ 117.00
US$ 120.00
US$ 120.00